Edema – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Edema – Drugs In Development, 2024 report and make more profitable business decisions.
Edema is a condition where excess fluid accumulation is observed in the limbs bilaterally, appearing as as puffiness or swelling. This condition can be temporary, depending on the cause of the condition. There are various etiological factors: long-standing, low protein levels, pregnancy, chronic kidney disease (CKD), congestive heart failure (CHF), liver cirrhosis, venous insufficiency, and lung conditions like emphysema. Physical examination is the primary diagnostic method, where the swollen part is pressed by the thumb to see an indentation. Other tests include urine tests, chest X-ray, and ECG, based on the patient’s medical history of causal conditions. Fluid restriction is the primary treatment step, followed by supportive care as needed. A low-salt diet is a non-pharmacological intervention for patients with edema.
The Edema drugs in development market research report provide comprehensive information on the therapeutics under development for Edema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Edema and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Edema | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 12 molecules, with 11 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Edema therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Edema pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Edema treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
4B Technologies (Suzhou) Co LtdAcademic Pharmaceuticals Inc
Alteogen Inc
Apeptico Research and Development Ltd
Biodexa Pharmaceuticals PLC
Deha Pharmaceutical LLC
Jiangxi Jemincare Group Co Ltd
Karl-Franzens-Universitat Graz
Opera Therapeutics
Paradigm Biopharmaceuticals Ltd
Sarfez Pharmaceuticals Inc
Toa Eiyo Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Edema reports